Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2032

1.

Obstructing Duodenal Diffuse Large B-cell Lymphoma with Peritoneal Lymphomatosis with Exceptional Response to R-CHOP.

Zaarour M, Busack C, Munker R.

Cureus. 2019 May 8;11(5):e4621. doi: 10.7759/cureus.4621.

2.

Genomic validation of three-tiered clinical sub-classification of high-risk prostate cancer.

Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL.

Int J Radiat Oncol Biol Phys. 2019 Jul 1. pii: S0360-3016(19)33398-X. doi: 10.1016/j.ijrobp.2019.06.2510. [Epub ahead of print]

PMID:
31271825
3.

Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis.

Barata PC, Magi-Galluzzi C, Gupta R, Dreicer R, Klein EA, Garcia JA.

Clin Genitourin Cancer. 2019 May 25. pii: S1558-7673(19)30159-4. doi: 10.1016/j.clgc.2019.05.021. [Epub ahead of print]

PMID:
31262501
4.

Reply to J.B. Aragon-Ching.

Rosenthal SA, Hu C, Sartor O, Feng FY, Sandler HM.

J Clin Oncol. 2019 Jul 1:JCO1901332. doi: 10.1200/JCO.19.01332. [Epub ahead of print] No abstract available.

PMID:
31260645
5.

Delayed Metastatic Melanoma to the Pharyngeal Tonsil in an African American Female.

Barton BM, Ramsey T, Magne JM, Worley NK.

Ochsner J. 2019 Summer;19(2):181-183. doi: 10.31486/toj.17.0083.

6.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR.

Clin Cancer Res. 2019 Jun 28. doi: 10.1158/1078-0432.CCR-18-3988. [Epub ahead of print]

PMID:
31253630
7.

Myeloid Sarcoma of the Testis in Children: Clinicopathologic and Immunohistochemical Characteristics With KMT2A (MLL) Gene Rearrangement Correlation.

El Jamal SM, Salama A, Marcellino BK, Abulsayen HA, Zhou X, Hassan M, Firpo-Betancourt A, Saad AG.

Appl Immunohistochem Mol Morphol. 2019 Jun 24. doi: 10.1097/PAI.0000000000000783. [Epub ahead of print]

PMID:
31241561
8.

Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.

Zahoor H, Mir MC, Barata PC, Stephenson AJ, Campbell SC, Fergany A, Dreicer R, Garcia JA.

Invest New Drugs. 2019 Jun 24. doi: 10.1007/s10637-018-00716-w. [Epub ahead of print]

PMID:
31231785
9.

Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs.

Hasan M, Marzouk MA, Adhikari S, Wright TD, Miller BP, Matossian MD, Elliott S, Wright M, Alzoubi M, Collins-Burow BM, Burow ME, Holzgrabe U, Zlotos DP, Stratford RE, Witt-Enderby PA.

Mol Pharmacol. 2019 Aug;96(2):272-296. doi: 10.1124/mol.119.116202. Epub 2019 Jun 20.

PMID:
31221824
10.

The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population.

Zhong C, Gragert L, Maiers M, Hill BT, Garcia-Gomez J, Gendzekhadze K, Senitzer D, Song J, Weisenburger D, Goldstein L, Wang SS.

Leuk Lymphoma. 2019 Jun 19:1-10. doi: 10.1080/10428194.2019.1617858. [Epub ahead of print]

PMID:
31215275
11.

Organizing Psychologists, Behavioral Scientists, and Allied Professionals: Formation of the Society of Behavioral Medicine's Palliative Care Special Interest Group.

Hoerger M, Ramos K, Ellington L, Perry LM, Pollak KI, Porter LS.

J Pain Symptom Manage. 2019 Jun 12. pii: S0885-3924(19)30307-0. doi: 10.1016/j.jpainsymman.2019.06.002. [Epub ahead of print] No abstract available.

PMID:
31200013
12.

Predictive Values of Fasting Glucose, Postload Glucose, and Hemoglobin A1c on Risk of Diabetes and Complications in Chinese Adults.

Lu J, He J, Li M, Tang X, Hu R, Shi L, Su Q, Peng K, Xu M, Xu Y, Chen Y, Yu X, Yan L, Wang T, Zhao Z, Qin G, Wan Q, Chen G, Dai M, Zhang D, Gao Z, Wang G, Shen F, Luo Z, Qin Y, Chen L, Huo Y, Li Q, Ye Z, Zhang Y, Du R, Cheng D, Liu C, Wang Y, Wu S, Yang T, Deng H, Li D, Lai S, Bloomgarden ZT, Chen L, Zhao J, Mu Y, Ning G, Wang W, Bi Y; 4C Study Group.

Diabetes Care. 2019 May 31. pii: dc181390. doi: 10.2337/dc18-1390. [Epub ahead of print]

PMID:
31152120
13.

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.

Schiff JP, Cotogno P, Feibus A, Steinwald P, Ledet E, Lewis B, Sartor O.

BMC Cancer. 2019 May 31;19(1):524. doi: 10.1186/s12885-019-5729-7.

14.

Paediatric and adult-onset male hypogonadism.

Salonia A, Rastrelli G, Hackett G, Seminara SB, Huhtaniemi IT, Rey RA, Hellstrom WJG, Palmert MR, Corona G, Dohle GR, Khera M, Chan YM, Maggi M.

Nat Rev Dis Primers. 2019 May 30;5(1):38. doi: 10.1038/s41572-019-0087-y. Review.

PMID:
31147553
15.

Association between advanced cancer patient-caregiver agreement regarding prognosis and hospice enrollment.

Trevino KM, Prigerson HG, Shen MJ, Tancredi DJ, Xing G, Hoerger M, Epstein RM, Duberstein PR.

Cancer. 2019 May 30. doi: 10.1002/cncr.32188. [Epub ahead of print]

PMID:
31145833
16.

Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models.

Sabol RA, Bowles AC, Côté A, Wise R, O'Donnell B, Matossian MD, Hossain FM, Burks HE, Del Valle L, Miele L, Collins-Burow BM, Burow ME, Bunnell BA.

Breast Cancer Res. 2019 May 22;21(1):67. doi: 10.1186/s13058-019-1153-9.

17.

Improving attribution of adverse events in oncology clinical trials.

George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS.

Cancer Treat Rev. 2019 Jun;76:33-40. doi: 10.1016/j.ctrv.2019.04.004. Epub 2019 Apr 25. Review.

PMID:
31108240
18.

Clear cell adenocarcinoma of the lung: a SEER analysis.

Komiya T, Guddati AK, Nakanishi Y.

Transl Lung Cancer Res. 2019 Apr;8(2):187-191. doi: 10.21037/tlcr.2018.10.13.

19.

The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.

Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:321-330. doi: 10.1200/EDBK_239187. Epub 2019 May 17.

PMID:
31099673
20.

RECK suppresses interleukin-17/TRAF3IP2-mediated MMP-13 activation and human aortic smooth muscle cell migration and proliferation.

Mummidi S, Das NA, Carpenter AJ, Yoshida T, Yariswamy M, Mostany R, Izadpanah R, Higashi Y, Sukhanov S, Noda M, Siebenlist U, Rector RS, Chandrasekar B.

J Cell Physiol. 2019 May 9. doi: 10.1002/jcp.28792. [Epub ahead of print]

PMID:
31074012

Supplemental Content

Loading ...
Support Center